Abstract

THE EFFICACY OF INFLIXIMAB AND ADALIMUMAB IN THE MANAGEMENT OF POSTERIOR NON-INFECTIOUS UVEITIS AT KING HUSSEIN MEDICAL CENTER

Feda’ A. Al Smadi, MD, *Ali Alawneh, MD, Alaa A. Al Smadi, pharmacist, Dua'a. T. Daradkeh, MD, Noor M. Al-Adwan, MD and Ahmed E. Khtatbeh, MD

ABSTRACT

Aim: to evaluate safety and efficacy of infliximab and adalimumab in the management of non-infectious uveitis at King Hussein Medical center. Method: this is a retrospective study conducted at King Hussein Medical Center. All patients who were started on infliximab or adalimumab for the treatment of posterior non-infectious uveitis were included in the study. The medical records of the patients were reviewed regarding age, gender, visual acuity, etiology of uveitis, duration of treatment, efficacy of biologics regarding frequency and severity of attacks before and after starting therapy and side effects of medications. The obtained data were analyzed. Results: 50 patients aged between 6 and 45 years with a mean age of (21±14) years. 40% of them were less than 18 years of age and 60% of them were males. The most common indication for using biologics was unsatisfactory response to conventional immune suppressive drugs. The most common known disease encountered among patients using biologics was Bechet’s disease in adults (47%) and juvenile idiopathic arthritis (JIA) in children (60%). There was no statistical difference regarding the duration of treatment, number of attacks of uveitis and the improvement in BCAV between infliximab and adalimumab. Allergic reaction developed in (25%) patients using infliximab and (6%) of patient using adalimumab. Conclusion: infliximab was as effective adalimumab in controlling non-infectious uveitis and improving patient’s visual acuity of those patient. Allergic reaction was significantly more among patients using infliximab than adalimumab.

Keywords: adalimumab, infliximab, non-infectious uveitis.